Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $283.99 ($1.4M) on 2026-09-03, disclosed to the SEC on 2026-09-08.
Scheduled sale ($1.4M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $283.99 | 300 | $85K | 6.0% |
| 2 | $285.17 | 1,800 | $513K | 35.9% |
| 3 | $286.36 | 2,115 | $606K | 42.3% |
| 4 | $287.53 | 385 | $111K | 7.7% |
| 5 | $288.98 | 400 | $116K | 8.1% |
| Total | $286.09 avg | 5,000 |
| $1.4M |
| 100% |
| Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |
| LGND | SELL | 2026-05-04 | $1.2M | — | Filing → |